CN110506054A - 经工程改造的多肽 - Google Patents

经工程改造的多肽 Download PDF

Info

Publication number
CN110506054A
CN110506054A CN201880024844.6A CN201880024844A CN110506054A CN 110506054 A CN110506054 A CN 110506054A CN 201880024844 A CN201880024844 A CN 201880024844A CN 110506054 A CN110506054 A CN 110506054A
Authority
CN
China
Prior art keywords
tfr
seq
sequence
polypeptide
construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880024844.6A
Other languages
English (en)
Chinese (zh)
Inventor
陈晓诚
米哈利斯·卡里奥利斯
罗伯特·C·威尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denali Therapeutics Inc
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of CN110506054A publication Critical patent/CN110506054A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70582—CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201880024844.6A 2017-02-17 2018-02-15 经工程改造的多肽 Pending CN110506054A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201762460692P 2017-02-17 2017-02-17
US62/460,692 2017-02-17
US201762543658P 2017-08-10 2017-08-10
US201762543819P 2017-08-10 2017-08-10
US62/543,658 2017-08-10
US62/543,819 2017-08-10
US201762583426P 2017-11-08 2017-11-08
US201762583314P 2017-11-08 2017-11-08
US62/583,426 2017-11-08
US62/583,314 2017-11-08
PCT/US2018/018445 WO2018152375A2 (en) 2017-02-17 2018-02-15 Engineered polypeptides

Publications (1)

Publication Number Publication Date
CN110506054A true CN110506054A (zh) 2019-11-26

Family

ID=61628465

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880024844.6A Pending CN110506054A (zh) 2017-02-17 2018-02-15 经工程改造的多肽

Country Status (6)

Country Link
US (2) US10457717B2 (enExample)
EP (1) EP3583119A2 (enExample)
JP (2) JP7577447B2 (enExample)
CN (1) CN110506054A (enExample)
CA (1) CA3053381A1 (enExample)
WO (1) WO2018152375A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4628586A3 (en) * 2017-02-17 2026-01-14 Denali Therapeutics Inc. Transferrin receptor transgenic models
CA3053381A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Engineered polypeptides
RS63818B1 (sr) 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
HUE062436T2 (hu) 2017-08-03 2023-11-28 Alector Llc Anti-trem2 antitestek és alkalmazási módszereik
WO2019032955A1 (en) * 2017-08-10 2019-02-14 Denali Therapeutics Inc. MODIFIED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
IL253984A0 (en) * 2017-08-14 2017-09-28 Yeda Res & Dev Immunotherapy against aranviruses that bind through transferrin receptor 1 (tfr1
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
BR112020013921A2 (pt) * 2018-01-10 2020-12-01 Denali Therapeutics Inc. polipeptídeos de ligação ao receptor de transferrina e usos destes
CA3109763A1 (en) * 2018-08-16 2020-02-20 Denali Therapeutics Inc. Engineered bispecific proteins
KR20210100086A (ko) 2018-10-04 2021-08-13 유니버시티 오브 로체스터 혈장 오스몰농도 조작에 의한 글림프 전달의 개선
JP7543290B2 (ja) 2019-02-20 2024-09-02 デナリ セラピューティクス インコーポレイテッド 抗ｔｒｅｍ２抗体及びその使用方法
BR112022012230A2 (pt) 2019-12-23 2022-08-30 Denali Therapeutics Inc Variantes de progranulina
US11124567B2 (en) * 2020-01-13 2021-09-21 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
CA3170338A1 (en) * 2020-02-19 2021-08-26 Denali Therapeutics Inc. Engineered anti-her2 bispecific proteins
EP4188422A4 (en) * 2020-07-30 2024-08-28 University of Washington Transferrin receptor binding proteins
CN115785251B (zh) * 2021-07-16 2024-12-24 百奥赛图(北京)医药科技股份有限公司 Tfr1基因人源化非人动物及其构建方法和应用
IL311003A (en) 2021-08-25 2024-04-01 Denali Therapeutics Inc Anti-2HER antibodies and methods of using them
CA3230796A1 (en) 2021-09-01 2023-03-09 Biogen Ma Inc. Anti-transferrin receptor antibodies and uses thereof
EP4694904A2 (en) 2023-04-13 2026-02-18 REGENXBIO Inc. Targeting aav capsids, methods of manufacturing and using same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1993378A (zh) * 2004-08-03 2007-07-04 转化技术制药公司 Rage融合蛋白及使用方法
CN101410411A (zh) * 2006-02-09 2009-04-15 转化技术制药公司 Rage融合蛋白及使用方法
WO2016077840A2 (en) * 2014-11-14 2016-05-19 Ossianix, Inc. TfR SELECTIVE BINDING COMPOUNDS AND RELATED METHODS
WO2016081643A1 (en) * 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5527527A (en) 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5260210A (en) 1989-09-27 1993-11-09 Rubin Lee L Blood-brain barrier model
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
FR2705194A1 (fr) 1993-05-21 1994-11-25 Transgene Sa Animal transgénique exprimant une transferrine d'origine humaine.
WO1999000150A2 (en) 1997-06-27 1999-01-07 Regents Of The University Of California Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
US7241449B1 (en) 1999-04-12 2007-07-10 Aventis Pasteur Limited Transferrin receptor genes of moraxella
EP1285272A2 (en) 2000-02-08 2003-02-26 University of British Columbia Compositions and methods for screening therapeutic agents
JP2001238681A (ja) 2000-03-03 2001-09-04 Japan Science & Technology Corp 共培養による血液脳関門再構築モデル
AU2002236499A1 (en) 2000-11-30 2002-06-11 Uab Research Foundation Receptor-mediated uptake of peptides that bind the human transferrin receptor
AU2002315398A1 (en) 2001-06-29 2003-03-03 Wyeth Methods and compositions useful for the prediction of blood-brain barrier permeation
US20030074141A1 (en) 2001-10-15 2003-04-17 Camitro Corporation Meta-models for predicting blood brain barrier penetration based on simple physicochemical descriptors
US7592143B2 (en) 2003-04-18 2009-09-22 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
WO2005076011A2 (en) 2004-01-30 2005-08-18 Xenoport, Inc. Use of glut1 transporter expressed in blood brain barrier cells for screening for pharmacologically active substances
GB0403490D0 (en) 2004-02-17 2004-03-24 Daniolabs Ltd Screening methods
FR2871162B1 (fr) 2004-06-02 2007-06-29 Univ Paris 7 Denis Diderot Materiau de surface modifiee, son procede de preparation et ses utilisations
WO2006056879A1 (en) 2004-11-29 2006-06-01 Institut National De La Sante Et De La Recherche Medicale (Inserm) Human blood brain barrier model
US8900865B2 (en) 2005-12-14 2014-12-02 The Invention Science Fund I, Llc Blood brain barrier device
JP5113332B2 (ja) 2005-12-19 2013-01-09 正美 丹羽 血液脳関門インヴィトロ・モデル、病態血液脳関門インヴィトロ・モデル、及びこれを用いた薬物スクリーニング方法、病態血液脳関門機能解析方法、病因解析方法
WO2007143711A2 (en) 2006-06-07 2007-12-13 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
US20080044847A1 (en) 2006-06-23 2008-02-21 Shusta Eric V Blood-Brain Barrier Model
AU2007285763B2 (en) 2006-08-18 2011-12-15 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
JP2010533170A (ja) 2007-07-12 2010-10-21 プロセンサ テクノロジーズ ビー．ブイ． 化合物を種々の選択された臓器、組織又は腫瘍細胞に標的化するための分子
WO2010014622A2 (en) 2008-07-28 2010-02-04 Fondazione Istituto Firc Di Oncologica Molecolare (Ifom) In vitro model for modulating the blood brain barrier and methods of screening
DK3241435T3 (da) 2009-07-08 2021-08-23 Kymab Ltd Dyremodeller og terapeutiske molekyler
US8417465B2 (en) 2009-11-04 2013-04-09 Cfd Research Corporation Synthetic microfluidic blood-brain barrier
US9255259B2 (en) 2010-02-09 2016-02-09 Sangamo Biosciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
WO2012055891A1 (en) 2010-10-29 2012-05-03 F. Hoffmann-La Roche Ag Murine model of inflammation with il33 n-terminal domain deletion
CN103443125B (zh) 2010-11-30 2019-05-03 霍夫曼-拉罗奇有限公司 低亲和力血脑屏障受体抗体及其用途
KR20140026372A (ko) 2011-02-02 2014-03-05 이무노퓨처 아이앤씨. 혈액-뇌 장벽을 투과하는 약물 전달체, 펩티드 및 이의 용도
RU2013150331A (ru) 2011-04-20 2015-05-27 Рош Гликарт Аг СПОСОБ И УСТРОЙСТВА ДЛЯ рН-ЗАВИСИМОГО ПРОХОЖДЕНИЯ ГЕМАТОЭНЦЕФАЛИЧЕСКОГО БАРЬЕРА
EP2568051A1 (en) * 2011-09-07 2013-03-13 Stallergenes S.A. Methods for identifying dendritic cell subsets, for determining if a patient is developing a regulatory or an effector immune response, and for determining response to immunotherapy
DK177327B1 (en) 2011-12-23 2013-01-14 Entomopharm Aps OPTIMIZED INSECT BASED EX VIVO MODEL FOR EXAMINATION OF BLOOD BRAIN BARRIER penetration and method of exposing the insect brain to chemical compounds
US9475840B2 (en) 2012-02-27 2016-10-25 Universitat De Barcelona Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs
WO2013177062A2 (en) 2012-05-21 2013-11-28 Genentech, Inc. Methods for improving safety of blood-brain barrier transport
US9513280B2 (en) 2012-08-28 2016-12-06 University Of Utah Research Foundation Microfluidic biological barrier model and associated method
MX367126B (es) 2012-08-29 2019-08-06 Hoffmann La Roche Transporte para atravesar la barrera hematoencefálica.
US10590393B2 (en) 2012-11-08 2020-03-17 Wisconsin Alumni Research Foundation Retinoic acid enhanced human stem cell derived blood brain barrier model
US9932559B2 (en) 2012-11-16 2018-04-03 The Johns Hopkins University Platform for creating an artificial blood brain barrier
PT2978840T (pt) 2013-03-26 2021-01-06 Univ Of Artois Um modelo de barreira hematoencefálica humana derivado de células estaminais
TWI523945B (zh) 2013-03-29 2016-03-01 Nat Univ Chung Cheng Establishment of blood - brain barrier model in
SG11201509566RA (en) 2013-05-20 2015-12-30 Genentech Inc Anti-transferrin receptor antibodies and methods of use
EA201600141A1 (ru) 2013-08-02 2016-09-30 Ф. Хоффманн-Ля Рош Аг Терапевтический слитый белок
WO2015101586A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
US9629801B2 (en) 2014-01-10 2017-04-25 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
CN103897033A (zh) 2014-03-31 2014-07-02 中国药科大学 转铁蛋白受体TfR特异性结合肽及其应用
ES2913205T3 (es) * 2014-05-13 2022-06-01 Bioatla Inc Proteínas biológicas activas condicionalmente
EP2995949A1 (en) 2014-09-09 2016-03-16 Institut Pasteur New in vitro blood brain barrier model
EP3221361B1 (en) * 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
WO2016090486A1 (en) 2014-12-09 2016-06-16 National Research Council Of Canada Human blood brain barrier model
US9988454B2 (en) * 2015-05-20 2018-06-05 Immunwork Inc. Peptide core-based multi-arm linkers for treating central nervous system diseases
WO2016202343A1 (en) 2015-06-19 2016-12-22 Aalborg Universitet A triple co-culture model of the blood-brain barrier using primary porcine brain endothelial cells, porcine pericytes and porcine astrocytes
JP7021955B2 (ja) 2015-06-24 2022-03-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ２及び血液脳関門受容体に特異的な三重特異性抗体及び使用方法
AU2016282334B2 (en) 2015-06-24 2022-07-21 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
CA2990785C (en) 2015-06-24 2024-11-12 Jcr Pharmaceuticals Co., Ltd. ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER
HK1247933A1 (en) 2015-06-24 2018-10-05 Jcr Pharmaceuticals Co., Ltd. Fusion protein containing bdnf
WO2017035119A1 (en) 2015-08-24 2017-03-02 National University Of Singapore Blood brain barrier model in a 3d co-culture microfluidic system
TWI791006B (zh) 2016-12-26 2023-02-01 日商Ｊｃｒ製藥股份有限公司 包含bdnf之融合蛋白質
TWI833178B (zh) 2016-12-26 2024-02-21 日商Ｊｃｒ製藥股份有限公司 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
CA3053381A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Engineered polypeptides
EP4628586A3 (en) 2017-02-17 2026-01-14 Denali Therapeutics Inc. Transferrin receptor transgenic models

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1993378A (zh) * 2004-08-03 2007-07-04 转化技术制药公司 Rage融合蛋白及使用方法
CN101410411A (zh) * 2006-02-09 2009-04-15 转化技术制药公司 Rage融合蛋白及使用方法
WO2016077840A2 (en) * 2014-11-14 2016-05-19 Ossianix, Inc. TfR SELECTIVE BINDING COMPOUNDS AND RELATED METHODS
WO2016081643A1 (en) * 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAKETOSHI MIZUTANI等: "Transferrin Receptor 1 Facilitates Poliovirus Permeation of Mouse Brain Capillary Endothelial Cells", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 *

Also Published As

Publication number Publication date
WO2018152375A2 (en) 2018-08-23
JP2023058568A (ja) 2023-04-25
EP3583119A2 (en) 2019-12-25
WO2018152375A3 (en) 2018-09-27
US11732023B2 (en) 2023-08-22
US20180237496A1 (en) 2018-08-23
CA3053381A1 (en) 2018-08-23
US10457717B2 (en) 2019-10-29
JP7577447B2 (ja) 2024-11-05
US20200262890A1 (en) 2020-08-20
JP2020508053A (ja) 2020-03-19

Similar Documents

Publication Publication Date Title
TWI797106B (zh) 經工程改造之轉鐵蛋白受體結合多肽
US11732023B2 (en) Engineered polypeptides
TWI821197B (zh) 經工程改造之轉鐵蛋白受體結合多肽
HK40018508A (en) Engineered transferrin receptor binding polypeptides
EA049739B1 (ru) Сконструированные полипептиды, связывающие трансферриновый рецептор

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication